Globus Medical, Inc. ( NYSE:GMED ) just released its latest quarterly report and things are not looking great.

Stock indexes on Friday settled slightly lower as the market traded cautiously ahead of weekend trade talks between the US and China.  Comments on social media from President Trump weighed on stocks ...

Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

On the heels of a first quarter sales dip, leaders remain confident in Globus Medical’s full-year success, according to a May 8 earnings call. 1. Globus Medical’s Excelsius robotic technologies are ...

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Globus Medical (GMED) to $80 from $100 and keeps an Overweight rating on the ...

BTIG analyst Ryan Zimmerman lowered the firm’s price target on Globus Medical (GMED) to $77 from $88 and keeps a Buy rating on the shares. The ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025.

Discover key Q1 2025 insights from Globus Medical, including revenue trends, the Nevro acquisition, free cash flow growth, and future strategies.

Medical alert systems make accessing help in an emergency easy. Whether you fall and injure yourself or experience another type of medical situation, these systems can dispatch help from an ...

Globus Medical now expects adjusted per-share earnings of $3 to $3.30 for the year, down from a prior outlook of $3.10 to $3.40. It backed its full-year sales forecast of $2.8 billion to $2.9 billion.

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Globus Medical expects full-year earnings in the range of $3 to $3.30 per share, with revenue in the range of $2.8 billion to $2.9 billion. This story was generated by Automated Insights ( ...